STUDY COMPARING VELIPARIB PLUS CARBOPLATIN AND PACLITAXEL VERSUS INVESTIGATOR'S CHOICE OF STANDARD CHEMOTHERAPY IN SUBJECTS RECEIVING FIRST CYTOTOXIC CHEMOTHERAPY FOR METASTATIC OR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WHO ARE CURRENT OR FORMER SMOKERS: